Study of Perioperative Chemotherapy Combined With Tirelizumab and Trastuzumab in the Treatment of GC/EGC
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Perioperative chemotherapy improves overall survival (OS) and disease-free survival (DFS)
compared with surgery alone in patients with resectable gastric adenocarcinoma (GA) or
gastro-oesophageal junction adenocarcinoma (GEJA). The addition of tirelizumab and
trastuzumab to chemotherapy improves outcomes in patients with HER2-positive advanced gastric
cancer (GC), and the investigators aimed to explore its role in the perioperative setting.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University